KTT24 Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide Key points
KTT23 Shared decision making Key points In the context of medicines optimisation, shared
KTT22 Chemotherapy dose standardisation Key points Chemotherapy dose standardisation
KTT16 Anticoagulants, including direct-acting oral anticoagulants (DOACs) Key points
KTT3 Lipid-modifying drugs Key points The NICE guideline on cardiovascular disease:
KTT7 Antipsychotics in people living with dementia Key points The risks and limited
KTT14 Wound care products Key points A large number of wound dressings are available
KTT17 Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI Key points
KTT6 Hypnotics Key points The risks associated with hypnotics (including melatonin)
KTT21 Medicines optimisation in chronic pain Key points Controlling chronic pain can
KTT19 Psychotropic medicines in people with learning disabilities whose behaviour challenges Key points
KTT20 Safer insulin prescribing Key points Several new insulin products have been launched
KTT12 Type 2 diabetes mellitus: medicines optimisation priorities Key points The NICE
KTT18 Multimorbidity and polypharmacy Key points Multimorbidity is associated with
KTT5 Asthma: medicines safety priorities Key points Inhaled corticosteroids (ICS) are
KTT9 Antimicrobial stewardship: prescribing antibiotics Key points Antimicrobial resistance
KTT13 Non-steroidal anti-inflammatory drugs Options for local implementation Review
KTT15 Biosimilar medicines Options for local implementation Biosimilar medicines have